388 related articles for article (PubMed ID: 31578455)
1. Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.
Wróbel A; Arciszewska K; Maliszewski D; Drozdowska D
J Antibiot (Tokyo); 2020 Jan; 73(1):5-27. PubMed ID: 31578455
[TBL] [Abstract][Full Text] [Related]
2. Toward Broad Spectrum Dihydrofolate Reductase Inhibitors Targeting Trimethoprim Resistant Enzymes Identified in Clinical Isolates of Methicillin Resistant
Reeve SM; Si D; Krucinska J; Yan Y; Viswanathan K; Wang S; Holt GT; Frenkel MS; Ojewole AA; Estrada A; Agabiti SS; Alverson JB; Gibson ND; Priestley ND; Wiemer AJ; Donald BR; Wright DL
ACS Infect Dis; 2019 Nov; 5(11):1896-1906. PubMed ID: 31565920
[TBL] [Abstract][Full Text] [Related]
3. Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: a minireview.
Periti P
J Chemother; 1995 Jun; 7(3):221-3. PubMed ID: 7562018
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim.
Rosowsky A; Forsch RA; Queener SF
J Med Chem; 2002 Jan; 45(1):233-41. PubMed ID: 11754594
[TBL] [Abstract][Full Text] [Related]
5. Dihydrofolate reductase as a target for chemotherapy in parasites.
Gangjee A; Kurup S; Namjoshi O
Curr Pharm Des; 2007; 13(6):609-39. PubMed ID: 17346178
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I.
Gangjee A; Jain HD; Kurup S
Anticancer Agents Med Chem; 2007 Sep; 7(5):524-42. PubMed ID: 17896913
[TBL] [Abstract][Full Text] [Related]
7. Dihydrofolate reductase inhibitors as antibacterial agents.
Hawser S; Lociuro S; Islam K
Biochem Pharmacol; 2006 Mar; 71(7):941-8. PubMed ID: 16359642
[TBL] [Abstract][Full Text] [Related]
8. 2,4-Diamino-5-(2'-arylpropargyl)pyrimidine derivatives as new nonclassical antifolates for human dihydrofolate reductase inhibition.
Algul O; Paulsen JL; Anderson AC
J Mol Graph Model; 2011 Feb; 29(5):608-13. PubMed ID: 21146434
[TBL] [Abstract][Full Text] [Related]
9. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
[TBL] [Abstract][Full Text] [Related]
10. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
Rosowsky A; Forsch RA; Queener SF
J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
[TBL] [Abstract][Full Text] [Related]
11. Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
Forsch RA; Queener SF; Rosowsky A
Bioorg Med Chem Lett; 2004 Apr; 14(7):1811-5. PubMed ID: 15026078
[TBL] [Abstract][Full Text] [Related]
12. Crystal Structures of Trimethoprim-Resistant DfrA1 Rationalize Potent Inhibition by Propargyl-Linked Antifolates.
Lombardo MN; G-Dayanandan N; Wright DL; Anderson AC
ACS Infect Dis; 2016 Feb; 2(2):149-56. PubMed ID: 27624966
[TBL] [Abstract][Full Text] [Related]
13. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1998 Mar; 41(6):913-8. PubMed ID: 9526565
[TBL] [Abstract][Full Text] [Related]
14. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
Bastien D; Ebert MC; Forge D; Toulouse J; Kadnikova N; Perron F; Mayence A; Huang TL; Vanden Eynde JJ; Pelletier JN
J Med Chem; 2012 Apr; 55(7):3182-92. PubMed ID: 22424148
[TBL] [Abstract][Full Text] [Related]
15. Increased substrate affinity in the Escherichia coli L28R dihydrofolate reductase mutant causes trimethoprim resistance.
Abdizadeh H; Tamer YT; Acar O; Toprak E; Atilgan AR; Atilgan C
Phys Chem Chem Phys; 2017 May; 19(18):11416-11428. PubMed ID: 28422217
[TBL] [Abstract][Full Text] [Related]
16. In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.
Barrow EW; Dreier J; Reinelt S; Bourne PC; Barrow WW
Antimicrob Agents Chemother; 2007 Dec; 51(12):4447-52. PubMed ID: 17875993
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of Staphylococcus aureus CM.S2 (IMCJ1454).
Sekiguchi J; Tharavichitkul P; Miyoshi-Akiyama T; Chupia V; Fujino T; Araake M; Irie A; Morita K; Kuratsuji T; Kirikae T
Antimicrob Agents Chemother; 2005 Sep; 49(9):3948-51. PubMed ID: 16127079
[TBL] [Abstract][Full Text] [Related]
18. Towards new antifolates targeting eukaryotic opportunistic infections.
Liu J; Bolstad DB; Bolstad ES; Wright DL; Anderson AC
Eukaryot Cell; 2009 Apr; 8(4):483-6. PubMed ID: 19168759
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of wild-type and mutant methicillin-resistant Staphylococcus aureus dihydrofolate reductase reveal an alternate conformation of NADPH that may be linked to trimethoprim resistance.
Frey KM; Liu J; Lombardo MN; Bolstad DB; Wright DL; Anderson AC
J Mol Biol; 2009 Apr; 387(5):1298-308. PubMed ID: 19249312
[TBL] [Abstract][Full Text] [Related]
20. Dihydrofolate reductase inhibitors for use as antimicrobial agents.
He J; Qiao W; An Q; Yang T; Luo Y
Eur J Med Chem; 2020 Jun; 195():112268. PubMed ID: 32298876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
